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Sequence 3' to the &Globin Gene 
By P. Moi, G. Loudianos, J. Lavinha, S.  Murru, P. Cossu, R. Casu, L. Oggiano, M. Longinotti, A. Cao, and M. Pirastu 
We have previously described a family of Northern Sardinian 
descent in  which the propositus was affected by thalassemia 
major resulting from compound heterozygosity for codon 39 
nonsense mutation and the p'lVS II nt  745 mutation and in 
which all heterozygotes for the p'lVS II nt  745 mutation had 
normal hemoglobin (Hb) A,  levels. To define the reasons for 
normal HbA,  levels in otherwise typical p-thalassemia het- 
erozygotes,  we cloned  and  sequenced the &thalassemia 
gene in cis to the p'lVS  II nt 745 mutation. The sequence 
analysis showed a single nucleotide substitution (G +  A) at 
position 69 nts (6+69) downstream to the polyA addition 
site. Dot blot analysis with an oligonucleotide probe comple- 
mentary  to the S+69  mutation detected this mutation in 
several heterozygotes for the p'lVS II nt  745 mutation from 
the proband's family, but failed to  show it either in  a group of 
normal  individuals  of  the  same  origin  or  in nonrelated 
HE HUMAN  &GLOBIN  gene  encodes  the  @-like  T  subunit (bglobin chain) of  the hemoglobin (Hb) A,, 
the minor fraction of  adult Hb. The &globin gene lies on 
chromosome  11  within  the  P-like  globin  gene  cluster. 
Reduced  (6')  or absent  (6") production  of  the  &-globin 
chains  is  the  hallmark  of  a  group  of  genetic  disorders 
referred  to as 6-thalassemias (S-thal).'  The clinical rele- 
vance of  6-thal is related to the fact that, when coinherited 
either in cis or in trans with P-thal, the resulting phenotype 
is characterized by  normal HbA, levels, thus confusing the 
identification  of  the  P-thal  carrier  state. The molecular 
bases for 6-thal have so far been elucidated solely in a few 
cases in individuals of  Italian and Belgian origin. Deletion, 
frameshift, and messenger RNA (mRNA) processing muta- 
tions have been  characteri~ed.~.~  In Japanese individuals 
with 6"-thal, &globin gene analysis showed only a T -+  C 
change at position -77  5' to the cap site, which is very close 
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heterozygotes for the p'lVS II nt 745 mutation of the same or 
different descent from the proband. The 6+69 (G +  A) muta- 
tion may be responsible for the low  6-globin output from the 
p'lVS  II nt  745 chromosome or could be a silent polymor- 
phism not affecting the function of the 8-globin gene. The 
normal G at position 69 is part of a sequence very similar to 
the core DNA (A/T)GATA(A/G)  motif (GATA box) that is a 
binding site for the GATA-1 protein. Gel-retardation assay 
has shown that a DNA fragment containing the GATA motif 
with  the G +A at position +69 has increased binding affinity 
for erythroid-specific DNA binding protein(s)  as compared 
with the wild-type sequence.  These findings  may suggest 
that  the S+69  mutation  is  responsible  for  the  deficient 
function of the in  cis &globin gene. 
0  1992 by The American Society of Hematology. 
to the CCAAC  This gene, however, showed a normal 
function on transient expression assay. 
A  few  years  ago, we  described  a family  of  Northern 
Sardinian extraction in which the propositus was affected by 
thal major resulting from compound heterozygosity for the 
codon  39  nonsense  mutation  and  the  P'IVS  I1 nt  745 
mutation and in which all heterozygotes for the P'IVS  I1 nt 
745 mutation had normal HbA, levels6  We postulated that 
the chromosome in which the P'  IVS I1 nt 745 mutation 
resides also carries a 6-globin gene unable to increase the 
&globin chain output in response to P-thal(6-thal). 
We report herein  the results of  cloning and sequence 
analysis of  the &globin gene from this normal HbA, P-thal 
determinant.  We  found  a  G + A  substitution  69  bp 
downstream to the polyA addition site in the &globin gene 
in cis to the P'IVS  I1 nt 745 mutation. This 6+69 mutation 
lying within a GATA-1 protein binding sequence increases 
the affinity of the GATA sequence for an erythroid-specific 
factor and was not detected either in normal individuals or 
in  heterozygotes for the P'IVS  I1 nt  745 mutation from 
other families, suggesting that it may be responsible for the 
low &chain output from the affected &globin locus. 
FAMILY STUDY 
The propositus  (IV-1) was a thal major  patient  of  Sardinian 
descent, in whom previous molecular analysis using allelic-specific 
oligonucleotide  (ASO) probes  showed  the  compound  heterozy- 
gous state for the codon 39 nonsense  mutation and the C +  G 
substitution at position 745 of  the IVS I1 of the P-globin gene.6  His 
father (111-2)  heterozygote for the p"39 is a high HbA, level thal 
carrier, while the  mother  heterozygote  for the P'IVS  I1  nt  745 
mutation showed normal HbA,  level. All the relatives from the 
maternal side were analyzed for the presence of  the P'IVS  I1 nt 
745  defect  using  the  same  methods.  We  found  that  all  the 
heterozygotes for this mutation were also normal HbA, level P-thal 
carriers,  as  shown  in  Fig  1  and Table  1.  Codon  39  nonsense 
mutation was contained in haplotype  I1 and the p'IVS  I1 nt 745 
mutation in haplotype VII. 
512  Blood, Vol79, No 2 (January 15). 1992: pp 512-516 
For personal use only. on November 7, 2014.  by guest    www.bloodjournal.org From 6-THAL DUE TO A SEQUENCE MUTATION  513 
TT 
I 
m 
Ip: 
2 
0 
11.2  11.511.6  11.4 
mm.8 
111.7  111.5  111.3  IVl 
Fig 1.  Pedigree of  the family studied  and dot  blot analysis of 
several members of this family with an AS0 probe for the 6+69 G +  A 
mutation are shown. (0)  p'lVS II nt 745 6+69; (.)  r39. 
MATERIALS AND METHODS 
DNA was isolated from white blood cells by  phenol-chloroform 
extraction using standard techniques.'  Restriction endonuclease 
analysis was performed according to Goossens and Kan (1981).' 
Polymorphism haplotype analysis at the @-globin  gene cluster was 
performed according to Orkin et al (1982).' Total genomic DNA 
from the propositus (GF) was digested with HindllI. The 16- to 
17-kb fraction of  the  digested  DNA  was  collected by  density 
sedimentation through a continuous sucrose gradient, ligated to a 
derivative of phage A, Charon 34, in the Hind111 unique site, and in 
vitro  packaged.  The  recombinant  phages  were  propagated  in 
Escherichia coli and phage clones with the 17-kb insert that spans 
from the 3' region of  the Ay-gene to the 5' region of  the @-globin 
gene were isolated. 
Recombinant phage DNA was then digested with HinclI and 
probed with  pseudo-6-globin  gene probe on Southern blots  to 
determine the linkage of  the different cloned human DNA frag- 
ments with haplotype  I1 or VII. The clones containing the human 
insert of  interest,  ie,  for Hinclllpseudo-@ restriction  fragment 
Table 1.  Hematologic Features in the Family Studied 
MCV  HbA,  olNot a 
1-2 
1-3 
1-4 
11-1 
11-2 
11-3 
11-4 
11-5 
11-6 
11-7 
11-8 
111-1 
111-2 
111-3 
111-4 
111-5 
111-6 
111-7 
IV-1 
85 
89 
82 
87 
64 
62 
66 
91 
85 
68 
78 
59 
68 
67 
62 
62 
82 
59 
79 
2.05 
2.22 
2.17 
2.86 
3.3 
3.0 
2.96 
2.68 
2.41 
2.92 
1.96 
3.74 
4.80 
3.0 
2.75 
2.57 
1.9 
2.53 
2.87 
- 
- 
0.96 
0.90 
1.97 
1.92 
0.94 
- 
1.47 
1  .o 
2.28 
1.42 
1.63 
2.36 
2.06 
1.02 
2.24 
Abbreviation: MCV, mean corpuscular volume. 
length  polymorphism  (RFLP) (linked  to  haplotype  VII). were 
grown and large DNA preparations were obtained. A 2.3-kb Psr  I 
fragment including the whole &globin gene from an informative 
primary clone was subcloned into a plasmid Blue-Scribe (Strata- 
gene). The 2.3-kb Ai l fragment was further digested with BamHl 
and EcoRl to yield three fragments (5'4.9 kb-0.9 kb-0.4 kb-3') of 
appropriate size to  be  inserted  in  MI3 phage. Sequencing was 
performed by  the dideoxy chain termination method'" using MI3 
universal primer and three other synthetic  oligonucleotides located 
within IVS-I, IVS 11, and 3' to cap site. DNA amplification by  the 
polymerase  chain  reaction  (PCR) was  performed as previously 
described."  Direct sequencing on amplified DNA was performed 
by  the  dideoxy  chain  termination  method  on  amplified  single- 
strand DNA"  using  the  T7 DNA  Polymerase  (Sequenase USB 
Corporation). Sequencing and autoradiography  were performed by 
standard  techniques.' To screen  for the  presence of  the 8+69 
substitution, we  have  performed dot  blot  analysis on  amplified 
DNA as previously described" with  two oligonucleotide  probes, 
one complementary to the 8+69 mutation and the other homolo- 
gous to normal  DNA at the same position. The sequence of  the 
oligonucleotides  was: 5' CTACAGATAAGGAGCACTTG 3' and 
5'  CAAGTGCTCCCTATCTGTAG 3'. respectively. 
Electrophoretic mobility shift assays (EMSA) were performed 
by  incubating for 10 minutes at 25°C 7.5  pg of  protein, 2.5  kg of 
poly dl-dc, and  15.OOO  cpm/0.2 ng of  probe end labeled with T, 
Kinase  and "P-ATP.  The samples were electrophoresed in  5% 
polyacrylamide  gel  with  50 mmol/L Tris Borate EDTA (TBE) 
buffer."  In  the  competition  experiment  nuclear  extracts were 
preincubated  for 5 minutes with  the  unlabeled  oligonucleotide 
before addition of  the probe. The DNA sequences of  the oligonu- 
cleotides used  in the EMSA assays are (only the sense strand is 
given):  8N,  CTCTACAGATAGGGAGCA; 6M.  CTCTACA- 
GATAAGGAGCA; NFE2, GATCTGCTGAGTCATGA. The oli- 
gonucleotide NFE2 contains the consensus sequence for both API 
(TGAGTCA)  and NF-E2 (GCTGAGTGA). Nuclear extracts  were 
prepared according to Ohlsson and Edlund (1986)." 
RESULTS 
&Globin gene analysis.  We studied several members of 
the family by  restriction  endonuclease  analysis with  dif- 
ferent restriction enzymes and did not detect any rearrange- 
ment or  deletion within the P-like globin gene cluster (data 
not shown). 
The &globin gene from the chromosome containing the 
P'IVS  I1 nt 745 was cloned and sequenced from position 
-360  5' to the cap  site to  343 nt 3' to the termination codon. 
The  sequence analysis showed a single base change G +  A 
at position nt 69 3' to the polyA  addition site (data not 
shown). The  presence of  this mutation was confirmed either 
by direct sequencing on amplified  DNA (Fig 2) or by dot 
blot analysis with an oligonucleotide probe complementary 
to the 6+69 G + A  mutation (Fig  1).  The DNA from 
several relatives of  this patient who were heterozygous for 
the P'IVS  I1  nt  745  mutation were screened by  dot blot 
analysis  for  the presence  of  the  6+69  mutation  in  the 
6-globin gene. The G --* A at position +69 was detected in 
all  the subjects tested  that carried  the P'IVS  I1  nt  745 
mutation, indicating linkage of  this &globin gene mutation 
with the P'IVS  I1 nt 745 mutation (Fig 1). 
To  establish 
whether the G +A at position +69 is the cause of 6-that or 
Screening for  6+69  (G +A)  mutation. 
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a silent polymorphism not affecting the function of the in cis 
&globin gene,  we  tested  by  dot  blot  analysis and  AS0 
probes on amplified DNA a group of both normal individu- 
als and  heterozygotes for  the  P+IVS I1 nt  745  mutation 
either of  Northern  Sardinian  origin, as the proband  (90 
normal chromosomes), or of different descent (30 normals 
and  35  heterozygotes for the  P'IVS  I1 nt  745 mutation). 
None of  the DNA tested was found to have the G +  A 
change  at  position  +69  (Table  2),  indicating  that  this 
nucleotide substitution is not a common polymorphism. 
The normal G at position +69 takes part in the 
formation of the sequence TACAGATAGG, which is very 
similar to the core DNA sequence (A/T)GATA(A/G), the 
DNA binding motif  for the GATA-1 binding protein."." 
This finding raises the possibility that the low &globin gene 
expression from the &globin gene containing the G +  A 
substitution  at  position  +69  may  be  related  to altered 
interaction  of  the  mutant  GATA sequence  of  the  6+69 
mutation with the GATA-1 binding protein. We have thus 
performed EMSA (Fig 3A) using two double-strand 18.mer 
oligonucleotides, one of  which  is  complementary  to  the 
mutant &globin gene sequence (even lanes) and the other 
to the normal &globin gene sequence at the same position 
(odd  lanes),  and  with  nuclear  extract  from  HeLa  and 
noninduced  and  dimethyl sulfoxide (DMSO)  hemin  in- 
duced K562 cells. As expected from previous reports, the 
binding  activity of  the  GATA  sequence  appears  to  be 
EMSA. 
Table 2.  Results  of the Screening  for the S+69 (0  +A)  Mutation 
No. 
Chromosomes  analyzed  155 
Normal  120 
From North Sardinia  90 
From South Sardinia  30 
Mediterranean areas  35 
With the pWS  II nt 745 mutation from different 
5' 
AIT 
G 
A 
T 
A 
A JG 
3' 
Fig 2.  Direct sequencing on amplified DNA of the 
S-globin gene  of  the  propositus (GF). On the  left, 
schematic  representation  of  the  3'  region  of  the 
S-globin gene. In the middle, autoradiogram of the 
DNA sequences around position +69. Two bands at 
the same position (+69)  indicate the presence of the 
mutation  C -, T  in  the  anticodon  strand  which 
corresponds to  a  G-A  substitution  in  the  codon 
strand. On the right, the general form of the GATA 
motif is indicated. 
erythroid specific and unaffected by  the induction state in 
K562. The mutant  DNA fragment displays much  higher 
binding affinity than the wild-type sequence. 
Absence of  competition with 
NF-E2 oligonucleotide  (Fig 3B) indicates that  the band 
shift observed is not related to NF-E2 or AP1 binding to the 
GATA motif  and suggests specific GATA binding by  an 
erythroid-specific protein. 
Competition experiments. 
DISCUSSION 
In this study we have analyzed by  cloning and sequence 
analysis the  6-globin gene in  cis to the  P'IVS  I1 nt 745 
mutation from a patient with thal major who is a compound 
heterozygote for this mutation and the codon 39 nonsense 
mutation  to determine the reasons for the normal HbA, 
levels found in all heterozygotes for the p+IVS  I1 nt  745 
mutation  from the  proband's  family.  We  found a single 
nucleotide  substitution  (G +  A)  at  position  +69 down- 
stream from the polyA addition site in the &globin gene in 
cis  to  the  P'IVS  I1 nt  745  mutation.  Oligonucleotide 
analysis  with  a  probe  complementary  to  this  mutation 
showed the 6+69 mutation in all p-thal heterozygotes for 
the P'IVS  I1 nt 745 mutation of  the proband's family and 
failed to detect this mutation both in normal persons and in 
unrelated heterozygotes for the P'IVS  I1 nt 745 mutation of 
Sardinian or different descent. These findings suggest that 
the 6+69 mutation is indeed responsible in some way for 
the defective function of the in cis &globin gene. 
This  mutation  may  negatively affect the  process of  3' 
mRNA end formation. However, the sequences in  the 3' 
untranslated region of the P-like globin gene necessary for 
the 3' mRNA end formation are limited to the AAUAAA 
sequence, which in the 6-globin gene is located at position 
+  106 nt downstream to the termination codon and, at least 
in the rabbit P-globin gene, to a sequence within a critical 
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Fig 3.  EMSA. (A) Lanes 1 and 2, no protein added. Lanes 3 through 
10.  band shift observed after incubation with crude nuclear extract 
from the following cell lines: uninduced K562 cells (3 and 4); hemin- 
induced K562 cells (5 and 6); DMSO-induced MEL cells (7 and 8); and 
HeLa cells (9 and 10). The probes used were double-strand 18-mer 
oligonucleotides corresponding to the human &globin  gene normal 
sequence (8N. odd lanes) and mutant sequence (8M, even lanes). (B) 
Competition  experiment  using K562 nuclear extracts and SM  oligonu- 
cleotide probe. Lane 1,  no protein added. Lane 2,  no competition. 
Lanes 3 through 8. competition  with 50- and 100-fold  molar excess of 
the indicated unlabeled oligonucleotides. 
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35-bp region extending from 3 nucleotides 5’  to 30 nucle- 
otides 3’ to the polyA addition site.” 
Alternatively,  it is worth  noting  that  the  normal  G at 
position  +69 takes part in  the formation of  the sequence 
TACAGATAGG, which is very similar to the core DNA 
sequence of the general form (A/T)GATA(A/G) (GATA 
This  DNA  sequence  binds  GATA-1,  a 
zinc-finger binding protein  restricted  to  erythroid, mega- 
caryocyte, and  mast  cell  lineages  that  activates  specific 
globin gene  expression.”  Binding sites of  GATA-1  have 
been  mapped  upstream  of  the  human  y-  and  @-globin 
geneslS.26.?J  and in the P-globin gene 3’ enhancer region.” 
However, no GATA-1 binding sites have been defined so 
far in the &globin gene region, although a number of  the 
(T/A)GATA(A/G) consensus motifs exist in this region. 
Single base substitutions of  the core GATA sequence are 
able to  modify the function of  the respective promoter/ 
enhancer.  Furthermore,  increased  activity of  the human 
Gy-globin gene promoter  bearing  a T +  C mutation  at 
position  -175  seems  to  be  mediated  by  the  GATA-1 
binding  protein.ls  In  this  context,  we  have  performed 
gel-retardation assay studies that have shown that the DNA 
fragment containing the G +  A mutation of  the 6-globin 
gene displays a higher affinity for erythroid-specific binding 
proteins  than  the  wild-type sequence.  This finding may 
suggest that the G +  A mutation of  the 8-globin gene may 
increase  the  affinity of  the  GATA sequence  3’ to  the 
&globin gene for a GATA binding protein, perhaps indicat- 
ing a  relationship  between  the  increased  affinity of  the 
mutated GATA motif and the low &chain production from 
the  affected  &globin  locus.  This  hypothesis,  however, 
contrasts  with  previous  studies”  that  have  shown  that 
GATA-1 is a positive regulator of  the y- and P-globin gene 
expression.  It should,  however, be noted  that  GATA-1- 
mediated  enhanced  activity  of  the  -175  Cy T + C 
mutation  was  found  to  be  not  associated  with  major 
differences  in  GATA-1  binding  in  the  gel-retardation 
assay.lS Furthermore, multiple copies of  the GATA-1 con- 
sensus sequence placed 3’ to a reporter gene resulted in a 
dramatic  reduction  of  the transcription  stimulation seen 
when  binding  sites were  inserted  5‘:’  We  also  have  to 
consider  that  the  activity  of  the  GATA motif  may  be 
influenced by  the sequence context in which it resides and 
that different GATA proteins have been recently defined:’ 
some of  which may  have a negative effect on  the  P-like 
globin gene expression. 
Further studies  either on  the function of  the  GATA 
motif 3‘ to the S-globin gene or on transient expression of 
the &globin gene containing the 6+69 mutation in heterol- 
ogous  cells  are  necessary  to  clarify  whether  the  6+69 
mutation is responsible for the defective function of  the 
&globin gene and the role played by  this 3’ GATA site in 
regulating S-globin gene expression. 
box).  IS. 17. IN.?II.22.?1 
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